BioCorRx (OTC:BICX) said today that it inked a confidentiality agreement with the National Institute on Drug Abuse, which will allow the group to share information and potentially work together on R&D and commercialization of BioCorRx’s therapies for opioid use disorder.
The National Institutes of Health division has also agreed to participate as an observer at the FDA’s pre-IND meeting for BioCorRx’s naltrexone implant slated to take place on Jan. 24.
Get the full story at our sister site, Drug Delivery Business News.